FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMABusiness Wire • 12/24/25
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)Business Wire • 12/01/25
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025Business Wire • 11/11/25
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease PortfolioZacks Investment Research • 10/16/25
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control GroupBusiness Wire • 10/16/25
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?The Motley Fool • 10/16/25
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo NordiskInvestors Business Daily • 10/15/25
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease pushReuters • 10/15/25
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)GlobeNewsWire • 10/15/25
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramBusiness Wire • 09/02/25
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025Business Wire • 08/11/25